EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC 3.0

Capecitabine versus Paclitaxel After CDK4/6 Inhibitor Progression in Hormone Receptor–Positive, HER2-Negative Metastatic Breast Cancer: A Real-World Study

Zeliha Birsin iD, Ali Kaan Güren, Vali Aliyev, Murad Guliyev iD, Seda Jeral, Selin Cebeci, Emir Çerme iD, Murat Günaltılı, Hamza Abbasov iD, Ebru Çiçek, Süheyla Atak, Murat Sarı iD und 2 weitere

Breast Cancer: Targets and Therapy · 2026-04 · Volume 18 · 1-13

DOI: 10.2147/bctt.s598598 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Breast Cancer: Targets and Therapy, 2026-04. Verfasst von Zeliha Birsin und 13 weiteren Autor:innen. Beteiligte Einrichtung: Department of Medical Oncology, Faculty of Medicine, Istanbul University-Cerrahpaşa, Istanbul, Turkey. Die Arbeit nennt 35 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 3.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Kein Abstract verfügbar.

Schlagwörter

Stichwörter der Autor:innen

CDK4/6 inhibitorscapecitabinehormone receptor–positive breast cancerpaclitaxelpost-CDK4/6 inhibitor treatmentreal-world study

Autor:innen und Institutionen

  • Department of Medical Oncology, Faculty of Medicine, Istanbul University-Cerrahpaşa, Istanbul, Turkey.
  • Department of Medical Oncology, Faculty of Medicine, Marmara University, Istanbul, Turkey.

ORCID-Profile: Zeliha Birsin, Murad Guliyev, Emir Çerme, Hamza Abbasov, Murat Sarı, Özkan Alan

Zitieren

APA

Birsin, Z., Güren, A. K., Aliyev, V., Guliyev, M., Jeral, S., Cebeci, S., Çerme, E., Günaltılı, M., Abbasov, H., Çiçek, E., Atak, S., Sarı, M., Demirci, N. S., & Alan, Ö. (2026). Capecitabine versus Paclitaxel After CDK4/6 Inhibitor Progression in Hormone Receptor–Positive, HER2-Negative Metastatic Breast Cancer: A Real-World Study. Breast Cancer: Targets and Therapy, Volume 18, 1-13. https://doi.org/10.2147/bctt.s598598

Vancouver

Birsin Z, Güren AK, Aliyev V, Guliyev M, Jeral S, Cebeci S, et al. Capecitabine versus Paclitaxel After CDK4/6 Inhibitor Progression in Hormone Receptor–Positive, HER2-Negative Metastatic Breast Cancer: A Real-World Study. Breast Cancer: Targets and Therapy. 2026;Volume 18:1-13. doi:10.2147/bctt.s598598

BibTeX
@article{Birsin2026,
  author = {Birsin, Zeliha and Güren, Ali Kaan and Aliyev, Vali and Guliyev, Murad and Jeral, Seda and Cebeci, Selin and Çerme, Emir and Günaltılı, Murat and Abbasov, Hamza and Çiçek, Ebru and Atak, Süheyla and Sarı, Murat and Demirci, Nebi Serkan and Alan, Özkan},
  title = {Capecitabine versus Paclitaxel After CDK4/6 Inhibitor Progression in Hormone Receptor–Positive, HER2-Negative Metastatic Breast Cancer: A Real-World Study},
  journal = {Breast Cancer: Targets and Therapy},
  year = {2026},
  volume = {Volume 18},
  pages = {1--13},
  doi = {10.2147/bctt.s598598}
}
Kostenlos starten →